welludr offers two kinds of medication, and their regulatory status is not the same - worth knowing before you choose a plan.
The compounded medicines are not FDA-approved. welludr's headline options - compounded semaglutide from $41/month and compounded tirzepatide from $71/month - are prepared by a compounding pharmacy. Compounded drugs are not reviewed by the FDA for safety, effectiveness or quality before they are sold. That is true of every compounded GLP-1 provider we rank, welludr included; it is a feature of compounding, not a mark against this provider specifically.
The brand-name options are different, and so is their labelling. welludr also lists brand-name Ozempic and Zepbound. Zepbound (tirzepatide) is FDA-approved for chronic weight management in adults with obesity, or overweight with at least one weight-related condition (Zepbound prescribing information, revised August 2026). Ozempic (semaglutide) is approved to improve blood sugar in adults with type 2 diabetes and to reduce certain cardiovascular and kidney risks in that group - not for weight loss (Ozempic prescribing information, revised May 2026). Prescribing Ozempic for weight loss is therefore an off-label use: legal and common, but a use the FDA has not evaluated for that purpose. The FDA-approved semaglutide for weight management is Wegovy, which welludr does not list.
Tirzepatide is one medicine, not two. The pricing page labels tirzepatide "GLP-1 + GIP". That describes the two receptor targets, not two separate drugs mixed together. Tirzepatide is a single molecule that binds to and activates both the GIP and the GLP-1 receptors (Zepbound label, section 12.1, read November 19, 2026).




